Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
Open Access
- 21 January 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 327 (7), 639-651
- https://doi.org/10.1001/jama.2022.0470
Abstract
On November 24, 2021, health authorities in South Africa reported the emergence of a new SARS-CoV-2 variant, B.1.1.529 (Omicron).1 Omicron has spread rapidly, and as of January 6, 2022, was identified in 149 countries across all 6 World Health Organization regions.2 Omicron was first detected in the US on December 1, 2021, and by January 1, 2022, was estimated to be responsible for 95% of sequenced new cases.3,4Keywords
This publication has 26 references indexed in Scilit:
- Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in IsraelThe Lancet Regional Health - Europe, 2021
- High-strength porous alumina ceramics prepared from stable wet foamsJournal of Advanced Ceramics, 2021
- Risk Factors Associated With COVID-19 Transmission Among US Air Force Trainees in a Congregate SettingJAMA Network Open, 2021
- Epidemiological Correlates of Polymerase Chain Reaction Cycle Threshold Values in the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clinical Infectious Diseases, 2020
- Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020Eurosurveillance, 2020
- Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic SamplesClinical Infectious Diseases, 2020
- The Use of Test-negative Controls to Monitor Vaccine EffectivenessEpidemiology, 2020
- Test-Negative DesignsEpidemiology, 2019
- The impact of selection bias on vaccine effectiveness estimates from test-negative studiesVaccine, 2018
- Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine EffectivenessAmerican Journal of Epidemiology, 2016